Research programme: antibody-drug conjugates - Daiichi Sankyo Company

Drug Profile

Research programme: antibody-drug conjugates - Daiichi Sankyo Company

Alternative Names: DS-7300

Latest Information Update: 05 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators; TROP2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Dec 2017 Daiichi Sankyo plans a phase I trial in Solid tumours (Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable) in Japan and USA (JapicCTI173812) (NCT03401385)
  • 27 Apr 2017 Preclinical trials in Solid tumours in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top